Prognostic value of nutritional risk index in esophageal cancer: A protocol for systematic review and meta-analysis.
Ze-Yuan Liu, Ben Liu
Kernaussage
High nutritional risk index (NRI) and geriatric nutritional risk index (GNRI) predict superior overall survival (HR = 1.78) and distant metastasis-free survival/progression-free survival/recurrence-free survival (HR = 1.95) in esophageal cancer patients, while low NRI/GNRI is associated with more lymph node metastasis, deeper tumor invasion, and advanced tumor stage.
Abstract
The nutritional risk index (NRI) and its modified version, the geriatric nutritional risk index (GNRI), are simple formula-based tools reflecting nutritional and inflammatory status. While several studies have investigated their prognostic value in esophageal cancer (EC), results remain inconsistent, and no prior meta-analysis has directly compared NRI and GNRI in this context. Therefore, this meta-analysis was conducted to thoroughly assess the prognostic significance of NRI/GNRI in EC. Possible studies were obtained from Embase, Web of Science, PubMed, and Cochrane Library from their inception to November 2024. A relative ratio (RR) and a hazard ratio (HR) were extracted and pooled to analyze the correlation between the prognosis of EC and NRI/GNRI. The final meta-analysis included 10 studies, with 2600 patients. As displayed in the pooled results, high NRI/GNRI predicted superior overall survival (HR = 1.78, 95% confidence interval [CI]: 1.53-2.07, P < .01) and distant metastasis-free survival/progression-free survival/recurrence-free survival (HR = 1.95, 95% CI: 1.52-2.51, P < .01). The association was presented between low NRI/GNRI and more lymph node metastasis (RR = 1.18, 95% CI: 1.01-1.38, P = .040), deeper tumor invasion (RR = 1.18, 95% CI: 1.01-1.38, P = .040), as well as advanced tumor stage (RR = 1.32, 95% CI: 1.10-1.58, P = .003). Both NRI and GNRI are independent prognostic factors in EC. Incorporating nutritional risk screening into routine clinical practice may support early intervention and improve treatment outcomes, particularly in surgical patients.
Kein medizinischer Rat. Die dargestellten Studien dienen der wissenschaftlichen Information und ersetzen keine ärztliche Beratung. Bei gesundheitlichen Fragen wende dich an eine approbierte Ärztin oder einen Arzt.
Quelle: PubMed Central / National Library of Medicine (NLM). Apollion steht in keiner Verbindung mit NLM und wird von NLM nicht empfohlen. Evidenzgrade bewerten die methodische Studienqualität — nicht die inhaltliche Richtigkeit.
Lizenz: CC BY — Inhalte werden ausschließlich aus Open-Access-Quellen mit kommerziell nutzbaren Lizenzen (CC0, CC BY, CC BY-SA) indexiert.